about
Current and future alternative therapies for beta-thalassemia majorCan homeopathy bring additional benefits to thalassemic patients on hydroxyurea therapy? Encouraging results of a preliminary study.Novel therapeutic candidates, identified by molecular modeling, induce γ-globin gene expression in vivo.Fetal globin induction in beta-thalassemia.Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond?Identification of novel small-molecule inducers of fetal hemoglobin using pharmacophore and 'PSEUDO' receptor models.Hydroxyurea Treatment in Transfusion-Dependent β-Thalassemia PatientsShort-chain fatty acids induce gamma-globin gene expression by displacement of a HDAC3-NCoR repressor complex.Developmental- and differentiation-specific patterns of human gamma- and beta-globin promoter DNA methylation.Liquid chromatography-mass spectrometric assay for quantitation of the short-chain fatty acid, 2,2-dimethylbutyrate (NSC 741804), in rat plasma.Butyrate histone deacetylase inhibitors.Molecular therapies in beta-thalassaemia.Discovering the genetics underlying foetal haemoglobin production in adults.Evaluation of safety and pharmacokinetics of sodium 2,2 dimethylbutyrate, a novel short chain fatty acid derivative, in a phase 1, double-blind, placebo-controlled, single-dose, and repeat-dose studies in healthy volunteers.A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia.Epigenetic Treatment of Neuropsychiatric Disorders: Autism and Schizophrenia.cAMP response element-binding protein 1 is required for hydroxyurea-mediated induction of γ-globin expression in K562 cells.Bioprotective carnitinoids: lipoic acid, butyrate, and mitochondria-targeting to treat radiation injury: mitochondrial drugs come of age.Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young β-thalassemia intermedia patients.Induction of foetal haemoglobin synthesis in erythroid progenitor stem cells: mediated by water-soluble components of Terminalia catappa.Short-term toxicity study of ST-20 (NSC-741804) by oral gavage in Sprague-Dawley rats.
P2860
Q26750906-6E18801E-B38D-4735-9AA1-45E65A4E2144Q33629906-2ABE8F85-B104-4CFC-9808-AEC6687B3866Q33922774-2CE6E89B-F0EB-42B4-930B-B51C7CC3C0DFQ34087414-EFF7A547-70D5-486F-AA84-6931E61B522CQ34322542-1FFA13B4-C858-4665-89B5-59C67E36E26CQ34678844-90B47C03-54E9-4913-81D2-4ADB3B63D737Q35213992-86A93DFC-EEFF-474A-9210-87EF4CB2281EQ35849050-932A0A99-33FB-42DF-AF92-DBC175652795Q35925062-E98F587A-9140-47EE-972B-ED0683253161Q36478403-E8A722E0-4A48-440C-B3FB-78D8CFFAF153Q36574546-448450EB-ECE4-421B-84BF-7CFB75CDFA9EQ36665342-7C436C94-F6A8-436A-8E6D-C0B3E4E7D7C7Q37432250-4FAAE277-F198-4987-8DAB-369D7FDE0C85Q37524864-89DE812B-87A4-40C4-A908-C4A69084DB94Q37674785-8073FA17-53F7-4FDA-BBCB-F9AA36069983Q38743021-E2526C07-D439-4A9F-8730-57D2F476D573Q39370653-4B3B8F35-3FE7-48D0-9BC7-EF5B78BCBC90Q41953858-D3D40B08-775D-4067-9817-7A51F6F7DC6BQ47828342-A438C86D-F80B-40C4-8465-F138B9CC4784Q47924851-4B6473E9-7A47-4AF7-B35A-D0C8854FCDFFQ50537208-FDA498D0-BB7E-4342-97EA-EE8DF63532C4
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Fetal globin induction--can it cure beta thalassemia?
@ast
Fetal globin induction--can it cure beta thalassemia?
@en
Fetal globin induction--can it cure beta thalassemia?
@nl
type
label
Fetal globin induction--can it cure beta thalassemia?
@ast
Fetal globin induction--can it cure beta thalassemia?
@en
Fetal globin induction--can it cure beta thalassemia?
@nl
prefLabel
Fetal globin induction--can it cure beta thalassemia?
@ast
Fetal globin induction--can it cure beta thalassemia?
@en
Fetal globin induction--can it cure beta thalassemia?
@nl
P2860
P1476
Fetal globin induction--can it cure beta thalassemia?
@en
P2093
Susan P Perrine
P2860
P356
10.1182/ASHEDUCATION-2005.1.38
P577
2005-01-01T00:00:00Z